Literature DB >> 24548338

Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.

E Kottenberg1, M Thielmann, P Kleinbongard, U H Frey, T Heine, H Jakob, G Heusch, J Peters.   

Abstract

BACKGROUND: Remote ischaemic pre-conditioning attenuates myocardial injury. Because sulphonylurea drugs interfere with ischaemic and anaesthetic pre-conditioning, we assessed whether remote ischaemic pre-conditioning effects are altered in sulphonylurea-treated diabetics.
METHODS: Using the database of our ongoing randomised, placebo-controlled study (ClinicalTrials.gov NCT01406678), we assessed the troponin I concentration area under curve (measurements: baseline, 1, 6, 12, 24, 48, and 72 h post-operatively) in sulphonylurea-treated diabetics (n = 27) and non-diabetics (n = 230) without and with remote ischaemic pre-conditioning (three 5-min periods of left upper arm ischaemia with 5-min reperfusion each) during isoflurane anaesthesia before two- to three-vessel coronary artery surgery.
RESULTS: Remote ischaemic pre-conditioning in non-diabetic patients evoked a 41% decrease in the troponin I concentration area under curve (514 ng/ml × 72 h ± 600 vs. 302 ± 190, P = 0.001) but no change (404 ng/ml × 72 h ± 224 vs. 471 ± 383, P = 0.62) in sulphonylurea-treated diabetics. There was no significant correlation between the troponin I concentration area under curve and arterial glucose concentrations, and the latter was not an independent confounder.
CONCLUSION: Cardioprotection by remote ischaemic pre-conditioning during isoflurane anaesthesia is abolished in sulphonylurea-treated diabetics.
© 2014 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24548338     DOI: 10.1111/aas.12278

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  19 in total

Review 1.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

Review 2.  Myocardial remote ischemic preconditioning: from cell biology to clinical application.

Authors:  Martín Donato; Ricardo J Gelpi; Eliana P Bin; Verónica D Annunzio
Journal:  Mol Cell Biochem       Date:  2021-06-14       Impact factor: 3.396

3.  Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.

Authors:  Joseph Wider; Vishnu V R Undyala; Peter Whittaker; James Woods; Xuequn Chen; Karin Przyklenk
Journal:  Basic Res Cardiol       Date:  2018-03-09       Impact factor: 17.165

Review 4.  Remote ischemic conditioning.

Authors:  Gerd Heusch; Hans Erik Bøtker; Karin Przyklenk; Andrew Redington; Derek Yellon
Journal:  J Am Coll Cardiol       Date:  2015-01-20       Impact factor: 24.094

Review 5.  Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury.

Authors:  Theo P Menting; Kimberley E Wever; Denise Md Ozdemir-van Brunschot; Daan Ja Van der Vliet; Maroeska M Rovers; Michiel C Warle
Journal:  Cochrane Database Syst Rev       Date:  2017-03-04

Review 6.  Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop.

Authors:  Jack M J Pickard; Hans Erik Bøtker; Gabriele Crimi; Brian Davidson; Sean M Davidson; David Dutka; Peter Ferdinandy; Rocky Ganske; David Garcia-Dorado; Zoltan Giricz; Alexander V Gourine; Gerd Heusch; Rajesh Kharbanda; Petra Kleinbongard; Raymond MacAllister; Christopher McIntyre; Patrick Meybohm; Fabrice Prunier; Andrew Redington; Nicola J Robertson; M Saadeh Suleiman; Andrew Vanezis; Stewart Walsh; Derek M Yellon; Derek J Hausenloy
Journal:  Basic Res Cardiol       Date:  2014-12-02       Impact factor: 17.165

Review 7.  ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies.

Authors:  Sandrine Lecour; Hans E Bøtker; Gianluigi Condorelli; Sean M Davidson; David Garcia-Dorado; Felix B Engel; Peter Ferdinandy; Gerd Heusch; Rosalinda Madonna; Michel Ovize; Marisol Ruiz-Meana; Rainer Schulz; Joost P G Sluijter; Linda W Van Laake; Derek M Yellon; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2014-10-24       Impact factor: 10.787

8.  A randomized trial of remote ischemic preconditioning and control treatment for cardioprotection in sevoflurane-anesthetized CABG patients.

Authors:  Rianne Nederlof; Nina C Weber; Nicole P Juffermans; Bas A M J de Mol; Markus W Hollmann; Benedikt Preckel; Coert J Zuurbier
Journal:  BMC Anesthesiol       Date:  2017-03-29       Impact factor: 2.217

Review 9.  Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection.

Authors:  Derek J Hausenloy; Hans Erik Bøtker; Peter Ferdinandy; Gerd Heusch; G André Ng; Andrew Redington; David Garcia-Dorado
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

Review 10.  Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2015-09-29       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.